Kornimate/medical-research-clean huggingface dataset:
prospective cohort on quality of sexual life among men who have sex with men treated for anal cancer with concurrent chemotherapy and intensity-modulated radiotherapy

Conditions: Anal Cancer; Quality of Life

Summary: treatment of anal cancer has been always linked to quality of life. recently, with development on radiotherapy technique, toxicities have been lowered with the maintenance of adequate rates of disease control. this trial intends to follow patients prospectively with questionnaires to evaluate sexual quality of life among patients who are who men who have sex with other men and have been subject to concurrent chemoradiotherapy with imrt technique.

in this prospective single-arm cohort, patients who are men who have sex with other men will be recruited to answer routine questionnaires on quality of life in general and sexual quality of life in specific, most validated and other waiting for validation in portuguese language. these questionnaires will be applied after the diagnose and before the beginning of the treatment, on the last day of treatment, and 3, 6 and 12 months after the treatment is completed. only patients who will be treated with concurrent chemotherapy will be recruited, and intensity-modulated radiotherapy technique is mandatory.

Eligibility criteria:
inclusion criteria: * anal cancer proven biopsy * men who have sex with other men * curative intent of treatment * imrt required * concurrent chemotherapy required exclusion criteria: * patients who have undergone surgery for anal cancer * patients who can't read, write or are unable to answer to questionnaire

Keywords: quality of sexual life intensity-modulated radiotherapy concurrent chemoradiotherapy
changes in prostate specific antigen levels during synergo therapy-intravesical chemotherapy instillations combined with hyperthermia

Conditions: Bladder Cancer

Summary: purpose: we determined whether synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (psa). materials and methods: we will treat 25 consecutive patients with bladder cancer with a 6-week course of synergo therapy, followed by cystoscopy at 6 weeks. blood samples for psa determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control. evaluating changes in psa level in patients undergoing treatment with synergo delivered local hyperthermia combined with intravesical instillation of mitomycin c for adjuvant treatment or pt. with recurrent tu of bladder post turt with bcgtreatment.


Eligibility criteria:
inclusion criteria: * recurrent transitional cell carcinoma of urinary bladder post endoscopic resection * psa prior synergo therapy application\<10 * normal rectal examination * patients willing to sign informed consent according exclusion criteria: * history of prostate cancer * previous history of tcc stage t2 or higher * invasive tu of bladder * prior pelvic radiotherapy or systemic chemotherapy * active prostatitis * active tuberculosis

Keywords: s/p transuretral resection of bladder tumor recurrent tumor after bcg treatment
study comparing healing with epidermal fractional blistergrafting (cellutometm) to acellular technique

Conditions: Burn Wound

Summary: the purpose of this study is to determine if healing occurs within 21 days of treatment with the use of the cellutometm device for fractional epidermal micro grafting compared with standard acellular techniques (creams and membrane dressings). healing will be determined by time to ≥90% epithelialization within 21 days of treatment. cosmesis (as assessed by vancouver scar scale (vss), patient observer scar assessment scale (posas), erythema, pigmentation, elasticity, thickness, and sensation) will be compared to standard techniques without application of skin cells (epidermal grafts = acellular) and will be measured twelve months post treatment application, ± 6 months.

hypothesis: the use of epidermal blister grafting by the cellutometm device in the treatment of superficial and mid-dermal burn wounds will demonstrate a difference in time to healing compared to burn wounds treated with standard acellular technique. primary objective: determine if the use of the cellutometm device will demonstrate a difference in healing time compared to standard acellular technique. final cosmetic outcomes (as assessed by vancouver scar scale (vss), patient observer scar assessment scale (posas), erythema, pigmentation, elasticity, thickness, and sensation) will be assessed and described at 12 months ± 6 months post treatment. secondary objectives: * determine if donor sites have any visible scarring with the use of the cellutometm. * determine acute outcomes of therapy such as time to healing as assessed by ≥90% epithelialization. * determine chronic outcomes of therapy (as assessed by vancouver scar scale (vss), patient observer scar assessment scale (posas), erythema, pigmentation, elasticity, thickness, and sensation).

Eligibility criteria:
inclusion criteria: 1. patients admitted or seen by the lvhn burn service with superficial to mid-dermal thickness burns will be considered for the study. 2. age ≥18 years old. 3. patients with a total body surface area (tbsa) burn \> 1% outside of the face, neck, feet or genitalia, where at least 2 areas are greater in size than 5x5cm2 or at least one area that is greater than 10cm2 exclusion criteria: 1. pregnant. 2. age \< 18 years old. 3. proposed study area on face, neck, genitalia, or feet.
impact of expanded peri operative warming

Conditions: Hypothermia; Complications

Summary: the purpose of this proposed study is to evaluate a normothermia protocol that includes preoperative warming and standard intra operative temperature management in patients undergoing general surgery.

this study was designed to evaluate a normothermia protocol that includes preoperative warming and standard intra operative temperature management in patients undergoing general surgery. it compares short term outcomes in patients for whom warming is expanded by commencing in the pre operative area and is maintained through post operative recovery versus patients receiving the standard warming at time of induction. patients were randomly assigned to either a warming blanket device or standard warming procedures. the study tested for differences in the rate of hypothermic events between the two groups. a secondary goal was to test for differences in the complication rate and patient satisfaction between the two groups. this study is testing the hypothesis that expanded warming significantly reduces rates of hypothermia and complications over standard warming used only during surgery.

Eligibility criteria:
inclusion criteria: * subjects are adult patients 18 years and older elective surgery of \> 1 hour exclusion criteria: * emergency and/or trauma cases * patients with diminished mental capacity unable to fill out or respond to survey questions.
mesenchymal stromal cells and osteoarthritis

Conditions: Osteoarthritis

Summary: osteoarthritis (oa) is one of the most frequent musculoskeletal disorders and represents the main indication for total joint arthroplasty. multipotent mesenchymal stromal cells (mscs) can be easily isolated and culture expanded from bone marrow aspirates and provide an excellent source of progenitor cells for cell-based regeneration strategies due to their ex vivo differentiation and proliferation capacity. although there are hints that mscs derived from oa patients may exhibit altered function the role of mscs with respect to disease development and progression of oa is not clearly understood to date. to assess whether advanced-stage oa affects mscs' suitability for musculoskeletal regenerative therapy, in the present study, we compare proliferation and differentiation potential of mscs from osteoarthritic versus healthy donors.

clinical data (range of motion of lower limb joints, sociodemographic score dataset, womac score, eq-5d score, harris hip score, radiological evaluation (oa group only), routine laboratory parameters, and bone metabolism parameters) osteogenic, chondrogenic, and adipogenic differentiation is proofed qualitatively by cell staining osteogenic, chondrogenic and adipogenic marker gene expression analysis using quantitative real-time rt-pcr cell-specific alkaline phosphatase (alp) activity assay large-scale gene expression profile fluorescence-activated cell sorting (facs)- cd44, cd105 (sh2; endoglin), cd106 (vascular cell adhesion molecule; vcam-1), cd166, cd29, cd73 (sh3 and sh4), cd90 (thy-1), cd117, stro-1 and sca-1 \[%\]

Eligibility criteria:
inclusion criteria: * indication for hip thr * primary osteoarthritis of the hip * patient's consent exclusion criteria: * secondary osteoarthritis of the hip * any malignancies * infectious disease * rheumatic disease * osteoporosis * any additional serious disease complicating the participation in this study

Keywords: osteoarthritis, mesenchymal stromal cells, proliferation
a single-blind, dose-titration study of kwa-0711 in patients with chronic constipation

Conditions: Chronic Constipation

Summary: the purpose of this study is to evaluate the efficacy and safety of titrated kwa-0711 dose in chronic constipation patients.


Eligibility criteria:
inclusion criteria: * the patients who experienced fewer than three spontaneous bowel movements per week for more than 6 months prior to the enrollment. * the patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation exclusion criteria: * patients who have secondary constipation caused by systemic disorder. * patients who have organic constipation. * patients who received intestinal resection

Keywords: chronic constipation constipation functional gastrointestinal disorders
preventive oral care

Conditions: Fever; Respiratory Infection

Summary: the purpose of the investigators project is to examine if the investigators may affect a reduction in respiratory infections in a pediatric long term care facility by institution of a comprehensive oral care program. the investigators wish to base their project on work such as of yoneyama et al 2002, which hypothesized and showed that "silent" aspiration of oropharyngeal contents is a causative factor in development of respiratory infection in elderly institutionalized clients. it was found that an advanced oral hygiene program greatly reduced the incidence of respiratory infection. although no similar research projects were found to have involved children, the investigators hope that a similar program of oral care will allow the investigators to likewise reduce the incidence of respiratory infection among the pediatric clients in our facility. the investigators propose to examine two groups of children which are fed by gastrostomy feedings only. one group will continue to receive oral care as performed today. the study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx. the investigators will retrospectively examine our records (a 12 month period) for febrile days, antibiotic use and hospitalization days due to respiratory causes. the investigators will then compare these to the febrile days, antibiotic use and hospitalizations to the 12 month period \[post implementation of the oral care program. the importance of this program is to examine whether by implementation of a relatively inexpensive and low-tech intervention may meaningfully reduce the morbidity and mortality due to respiratory infection among our clients (which from our experience is the main cause of morbidity and mortality in the investigators institution). the investigators expect that by reducing the incidence of respiratory disease among our clients that the investigators will greatly reduce suffering among the children and their families, improve their quality of life and ease the financial and organizational burdens as a result of caring for respiratory infections. as was noted before, no prior research was found which studied the pediatric population in a long term care facilities. it is our belief that this project represents a unique research opportunity which may bring great benefit to the children and caregivers.


Eligibility criteria:
inclusion criteria: * clients who receive gastrostomy feedings only * aleh infirmary exclusion criteria: * oral feeding

Keywords: antibiotics hospitalization oral care
study of stapokibatrt in children subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(pk), pharmacodynamics(pd) and immunogenicity of stapokibatrt in children with moderate-to-severe atopic dermatitis.


Eligibility criteria:
inclusion criteria: * age ≥ 2 and ≤ 11 years old. * diagnosis of ad according to the american academy of dermatology consensus (2014) criteria. * with moderate-to-severe ad, and inadequate response to topical medications. exclusion criteria: * prior treatment with stapokibart * treatment with dupilumab within 13 weeks prior to the baseline visit, or treatment with anti-ige(immunoglobulin e) monoclonal antibody，other biological agents within 5 half-lives prior to the baseline visit . * treatment with immunosuppressants/immunomodulatory drugs, ultraviolet therapy, or systemic traditional chinese medicine for ad within 4 weeks prior to the baseline visit. * treatment with a topical corticosteroids (tcs), topical calcineurin inhibitor (tci) or topical phosphodiesterase-4(pde-4) inhibitor within 1 weeks prior to the baseline visit. * history of atopic keratoconjunctivitis invading cornea. * acute attacks of atopic dermatitis within 4 weeks prior to the baseline visit. * planned major surgical procedure during the patient's participation in this study.
enhancing inpatient psychotherapeutic treatment with online self-help : acceptance and efficacy

Conditions: Depression

Summary: the purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. the patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.the investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.


Eligibility criteria:
inclusion criteria: * inpatient treatment * private internet access * informed consent * age between 18 and 65 years * knowledge of the german language * score in the bdi-ii \> 13 and clinical diagnosis of a depression (icd-10: f32.x, f33.x, f34.1, f43.2) verified by the inpatient therapist exclusion criteria: * psychosis * current alcohol or drug dependency * borderline, antisocial, schizoid or schizotypal personality disorder * anorexia nervosa * life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder
safety of leaving cook balloon uterine stent in uterus for one month

Conditions: Intrauterine Adhesion

Summary: to use cook balloon uterine stent to prevent intrauterine adhesion (iua), and to see if leaving it in the uterus will cause uterine infection.

background：intrauterine adhesion (iua) can cause infertility. hysteroscopic surgery can effectively treat most iua. in order to prevent adhesion reformation after surgery, most gynecologists will prescribe high-dose estrogen to stimulate endometrial growth, and leave an iud or a foley catheter in uterus for 1-3 months. but neither iud nor foley catheter conform to the uterine cavity. the cook balloon uterine stent was designed to fit into the uterine cavity. but it was designed to tamponade the uterus to prevent post-operative uterine bleeding. it's not known if it can be left in the uterus for 30 days. study design：uterine culture was done before hysteroscopic surgery, and 30 days later. the study group comprise patients with uterine stent; the control group comprise patients who undergo hysteroscopic surgeries but without uterine stent. method：immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity. the removed uterine stent was sent for bacterial culture too. the same procedures are done for patients with and without uterine stent. the bacterial counts will be compared before and after hysterosocpic surgeries, and between the two groups of patients. effect：if leaving the uterine stent in the uterus up to 30 days does not cause bacteria to grow, we can be confident to leave the stent for 30 days.

Eligibility criteria:
inclusion criteria: * intrauterine adhesion women exclusion criteria: * allergic to cook balloon uterine stent

Keywords: intrauterine adhesion cook balloon uterine stent
a study measuring asthma control in pediatric and adolescent subjects whose asthma is worsened by activity or exercise

Conditions: Bronchospasm; Activity/Exercise Induced Bronchospasm

Summary: during this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. certain office visits will include physical exams, medical history review, exercise challenge test (walking/running on a treadmill), electrocardiogram (ecg) tests, and lung function tests. all study related medications and medical examinations are provided at no cost. all study drugs are currently available by prescription to patients 4 years and older.


Eligibility criteria:
inclusion criteria: * diagnosed with persistent asthma for 3 months or longer. * experienced worsened asthma symptoms during physical activity. * using an inhaled steroid for the previous 4 weeks or longer (such as aerobid, azmacort, flovent, pulmicort, qvar, and vanceril). exclusion criteria: * used systemic steroids as either liquids, pills, or injections to treat asthma within the previous 3 months. * have only intermittent, seasonal, or exercise-induced asthma, and not persistent asthma. * admitted to a hospital within the previous 6 months due to asthma symptoms. * any poorly controlled medical conditions that may make study participation unsafe or inappropriate in the opinion of the study physician (such as cystic fibrosis, congenital heart disease, insulin dependent diabetes, glaucoma, drug allergies, etc.) * the study physician will evaluate other medical criteria.

Keywords: asthma bronchospasm
mother-infant signalling during breastfeeding

Conditions: Breastfeeding Women

Summary: primary hypotheses 1. the use of a relaxation tape by breastfeeding mothers that will be given starting at week 2 postpartum, will result in : i) reduced maternal stress and anxiety ii) the production of a higher volume of breast milk iii) lower milk cortisol concentrations iv) favourable effects on infant behaviour (less crying, more sleeping) v) higher milk intake by the infant vi) more optimal growth, specifically higher lean mass and lower fat mass (body composition) secondary hypotheses (i) infant temperament/behaviour and gender influence milk and energy intake and hence early growth and body composition (ii) non-nutrient factors in breast milk (hormones including ghrelin and leptin) influence infant behaviour and feeding patterns and hence infant growth and body composition.


Eligibility criteria:
inclusion criteria: primiparous mother with singleton pregnancy infant is singleton and born at term (37-42 week of gestation) infant birth weight of \>2500 g (5,5 pounds or 5 pounds and 8,2 ounces) mother and infant are generally healthy (free of serious illness that can affect breastfeeding or nursing infant, or energy balance of the infant). no current or recent involvement in other research studies that could potentially affect any of outcome measures. mother speaks and understands either english only or english and malay (some questionnaires are in english) exclusion criteria: mother or baby has a major illness that affects nursing or breastfeeding, or affects energy balance of the infant. mother smokes mothers who do not exclusively breastfeed their infant -

Keywords: breastfeeding, relaxation, anxiety, infant growth
diagnosis of short stature in children : study of a cohort of small-sized consulting patients

Conditions: Short Stature; Growth Delay

Summary: many patients consult in pediatric endocrinology because of their small size. in the majority of cases, this growth delays can be explained by a hormonal, gastroenterological cause, or a chronic disease. sometimes the reason for stunted growth can be constitutional bone disease, a genetic cause of short stature that is still underdiagnosed. the investigators wish to describe and take stock of the various additional analyzes carried out and the various diagnoses made in patients who consulted in endocrino-pediatrics at the montpellier university hospital due to their short stature, in 2017 and 2018, in order to better screen patients with constitutional bone disease


Eligibility criteria:
inclusion criteria: all the children who consulted for the first time because of their short stature, in pediatric endocrinology at the montpellier university hospital between january 2017 and december 2018 exclusion criteria: patient already undergoing specialized medical follow-up due to his small size major patient

Keywords: constitutional bone disease pediatrics
a study of surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors

Conditions: Pancreatic Neuroendocrine Tumor

Summary: pnens still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in china. at present, there is no standard adjuvant therapy for pnen, and prospective studies are still lacking. this study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pnet, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.


Eligibility criteria:
inclusion criteria: * pnets lesions pathologically classified as who grade 1/ 2/ 3; * g2/3-net with at least one high-risk postoperative recurrence factor, including but not limited to lymph node metastasis, neurovascular invasion, pancreatic duct dilation, tumor \>4cm, positive resection margin, etc.; or g1-net with lymph node or remote transfer; * complete surgical resection (r0 or r1 was achieved) ; * adjuvant treatment was performed within 6-12 weeks after surgery; * have received whole-body 68ga pet-ct examination within the past six months; exclusion criteria: * urinalysis shows urine protein ≥ 2+ and 24-hour protein quantity test shows urinary protein ≥1 g; * under anti-hypertension treatment, still uncontrolled hypertension, defined as: systolic blood pressure ≥ 150 mmhg or diastolic blood pressure ≥ 100 mmhg; * clinically significant cardiovascular disease, including but not limited to, acute myocardial infarction within 6 months prior to enrollment, severe/unstable angina pectoris or coronary artery bypass grafting, congestive heart failure according to the new york heart association (nyha) classification ≥ 2; ventricular arrhythmias which needs drug treatment; lvef (lvef) \<50%;